UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.09 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 85.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 83,231 shares of the company's stock after selling 493,214 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Amphastar Pharmaceuticals worth $3,090,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Boston Partners purchased a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at $15,778,000. Wealthfront Advisers LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $9,268,000. Systematic Financial Management LP bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $9,147,000. Dimensional Fund Advisors LP boosted its position in shares of Amphastar Pharmaceuticals by 9.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after purchasing an additional 105,288 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in shares of Amphastar Pharmaceuticals by 402.4% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 118,851 shares of the company's stock valued at $4,413,000 after purchasing an additional 95,192 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ AMPH opened at $25.52 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 8.51, a price-to-earnings-growth ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The business has a 50-day moving average price of $24.68 and a 200-day moving average price of $31.71.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Wells Fargo & Company lowered their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $32.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.